Claims for Patent: 10,376,580

Summary for Patent: 10,376,580

Title:	Methods of treating cancer with antibody-albumin nanoparticle complexes comprising albumin, trastuzumab, and paclitaxel
Abstract:	This invention relates to antibody-albumin nanoparticle complexes comprising albumin, trastuzumab, and paclitaxel, wherein the nanoparticle complex has been pre-formed in vitro such that the nanoparticle complex has antigen-binding specificity (e.g., HER2 binding specificity), for the purpose of providing cancer (e.g., HER2-related cancer) treatments in a subject in need thereof.
Inventor(s):	Markovic; Svetomir N. (Rochester, MN), Nevala; Wendy K. (Rochester, MN)
Assignee:	Mayo Foundation for Medical Education and Research (Rochester, MN)
Application Number:	15/412,554
Patent Claims:	1. A method for treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and antibody-albumin nanoparticle complexes, said complexes comprising albumin, an antibody with binding specificity for HER2, and paclitaxel, wherein the nanoparticle complexes have been pre-formed in vitro by mixing aqueous albumin-paclitaxel nanoparticles with the antibody under conditions to form the nanoparticle complexes, such that the nanoparticle complexes have HER2 binding specificity, wherein, the cancer expresses HER2, wherein the antibody is trastuzumab, and wherein the average diameter of greater than 60% of said complexes is between 0.1 .mu.m to 0.95 .mu.m. 2. The method of claim 1, wherein the average diameter of greater than 60% of said complexes is between 0.1 .mu.m and 0.9 .mu.m. 3. The method of claim 1, wherein the average diameter of greater than 60% of said complexes is between 0.1 .mu.m and 0.3 .mu.m. 4. The method of claim 1, wherein the ratio of albumin-paclitaxel nanoparticle to antibody is between 5:1 and 1:2.5. 5. The method of claim 1, wherein the pharmaceutical composition is administered by intravenous injection. 6. The method of claim 1, wherein the subject is a human. 7. The method of claim 1, wherein the cancer is breast cancer. 8. The method of claim 1, wherein the therapeutically effective amount is between about 30 mg/m.sup.2 and about 70 mg/m.sup.2 antibody. 9. The method of claim 1, wherein the therapeutically effective amount is between about 5 mg/kg and about 20 mg/kg antibody. 10. The method of claim 1, wherein the therapeutically effective amount is between about 50 mg/m.sup.2 and about 175 mg/m.sup.2 albumin-paclitaxel nanoparticles. 11. The method of claim 1, wherein the pharmaceutical composition is administered from about once a month to about three times a month. 12. The method of claim 1, wherein the pharmaceutical composition is administered three times per 28 day cycle for at least two cycles. 13. The method of claim 1, wherein said composition comprises an alkylating agent. 14. The method of claim 13, wherein said alkylating agent is a platinum compound. 15. The method of claim 1, wherein the pharmaceutically acceptable carrier is saline, water, lactic acid, mannitol, or a combination thereof.

Details for Patent 10,376,580

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2032-10-01
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2032-10-01
Genentech, Inc.	HERCEPTIN HYLECTA	trastuzumab and hyaluronidase-oysk	Injection	761106	02/28/2019		2032-10-01